Will Zaynich Drug's Fast-Track Review Speed Europe Approval?

Wockhardt Group's Zaynich drug, a novel antibiotic combination of Zidebactum and Cefepime, has received fast-track review status from the European Medicines Agency (EMA) for the treatment of serious bacterial infections, including severe urinary infections, hospital-acquired pneumonia, and life-threatening blood infections.